Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

Summary

The main objective of the study is to determine the pharmacokinetics profile of Subgam-VF. The secondary objectives are to assess the safety of Subgam-VF and refine the dose adjustment coefficient for Subgam-VF needed for subjects switching from prior intravenous immunoglobulin (IGIV) therapy.

Timeline

Start

2015-08-20

Primary completion

2017-05-25

Completion

2017-05-25

Drugs

Indications